“Pembrolizumab in PD-L1-Positive Advanced Non-Small Cell Lung Carcinoma: A Meta-Analysis of Survival Benefits and Immune-Related Toxicity Events Patterns: Original Scientific Article”. ADMET and DMPK, vol. 13, no. 5, 2956, Oct. 2025, https://doi.org/10.5599/admet.2956.